Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 11—November 2006
Research

Clostridium difficile PCR Ribotypes in Calves, Canada

Alexander Rodriguez-Palacios*Comments to Author , Henry R. Stämpfli*, Todd Duffield*, Andrew S. Peregrine*, Lise A. Trotz-Williams*, Luis G. Arroyo*, Jon S. Brazier†, and J. Scott Weese*
Author affiliations: *University of Guelph, Guelph, Ontario, Canada; †University Hospital of Wales, Cardiff, United Kingdom3

Main Article

Table 3

MIC50 and MIC90 range and resistance frequencies of 30 bovine Clostridium difficile isolates to 4 antimicrobial drugs by E-test on Muller-Hinton agar after 48 h of incubation*

Drug MIC50, μg/mL MIC90, μg/mL Range, μg/mL Resistant isolates, % (no. resistant/no. tested), MIC (μg/mL) Overrepresented PCR ribotypes (no.)
Vancomycin 0.5 0.75 0.25–1.5 0 0
Metronidazole 0.38 0.75 0.125–2.0 0 0
Levofloxacin 32 32 4 to >32 73 (22/30), >32 B89 (9/9), C129 (2/2), D189 (4/4), other 3 ribotypes (7 isolates)
Clindamycin 16.0 >256 6 to >256 73 (22/30), >12; 37 (11/30), >256 B89 (9/9), C129 (2/2)

*The breakpoints used were vancomycin susceptible, <4.0 μg/mL; vancomycin resistant, >32.0 μg/mL; metronidazole susceptible, <8.0 μg/mL; metronidazole resistant, >32.0 μg/mL; clindamycin susceptible, <2.0 μg/mL; clindamycin resistant >8.0 μg/mL; levofloxacin susceptible, <2.0 μg/mL; levofloxacin resistant, >8.0 μg/mL.

*The breakpoints used were vancomycin susceptible, <4.0 μg/mL; vancomycin resistant, >32.0 μg/mL; metronidazole susceptible, <8.0 μg/mL; metronidazole resistant, >32.0 μg/mL; clindamycin susceptible, <2.0 μg/mL; clindamycin resistant >8.0 μg/mL; levofloxacin susceptible, <2.0 μg/mL; levofloxacin resistant, >8.0 μg/mL.

Main Article

Page created: October 14, 2011
Page updated: October 14, 2011
Page reviewed: October 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external